Live Breaking News & Updates on Nct05580562

Stay updated with breaking news from Nct05580562. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

ONC201 Looks to Prove Efficacy in Trial For Rare H3K27M-Mutated Diffuse Midline Gliomas

The dopamine receptor D2 antagonist ONC201 is under evaluation in patients with H3K27M-mutated diffuse midline glioma in the phase 3 ACTION trial. ....

North Carolina , United States , University Of Pennsylvania , University Of North Carolina , Stephen Bagley , Ashley Sumrall , Hospital Of The University Pennsylvania , University Of North Carolina Chapel Hill , Abramson Cancer Center , Atrium Health Carolinas Medical Center , Atrium Health Levine Cancer Institute , Internal Medicine , Medical Oncology , North Carolina Chapel Hill , Phase Studies Pave , Data Shows Tolerable Safety Profile , Patients With H3k27m Mutated Diffuse Midline Glioma , Action Trial , The Hospital Of University Pennsylvania , University Of North Carolina Chapel Hill ,

Dr Bagley on the ACTION Trial of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas

Stephen Bagley, MD, MSCE, discusses the phase 3 ACTION trial evaluating ONC201 in H3K27M-mutant diffuse midline gliomas. ....

United States , Stephen Bagley , University Of Pennsylvania Hospital , Pennsylvania Hospital , Penn Medicine , Phase 3 Action Trial , Onc201 I , H3k27m Mutant Diffuse Midline Gliomas ,